Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 592

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 592
---
 rights to third parties, providing research
services under licensing and collaboration agreements as well as revenue from government grants.

Kineta has never been profitable and
have incurred operating losses in each period since inception. Kineta’s net losses were $17.1 million for the year ended December 31, 2024 and $14.1 million for the year ended December 31, 2023. As of December 31, 2024,
Kineta had an accumulated deficit of $182.9 million.

Kineta expects to incur significant expenses and continued operating losses for
at least the next several years as Kineta initiates and continues the clinical development of, and seek regulatory approval for, Kineta’s product candidates and add personnel necessary to advance Kineta’s pipeline of clinical-stage product
candidates. In addition, operating as a publicly-traded company will involve the hiring of additional financial and other

392

personnel, and the incurrence of substantial other costs associated with operating as a public company. Kineta expects that Kineta’s operating losses will fluctuate significantly from
quarter to quarter and year to year due to timing of clinical development programs and efforts to achieve regulatory approval.

From
inception to December 31, 2024, Kineta has raised cash from sales and issuances of common stock and borrowings under notes payable. As of December 31, 2024, Kineta had cash of $ 634,000, and there is substantial doubt about Kineta’s ability to
continue as a going concern. For more information, see the risk factor entitled, “Kineta identified conditions and events that raise substantial doubt about its ability to continue as a going concern, Kineta needs substantial additional funding, and if Kineta is unable to raise capital when needed or on favorable terms, its business, financial condition, and results of operation could be materially and adversely affected.”

The Merger

On December 11, 2024,
we entered into the Merger Agreement, by and among TuHURA, Merger Subs, and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta. Pursuant to the terms of the Merger Agreement, among
other things and subject to the terms and conditions set forth therein, Merger Sub I will undergo the First Merger, with the Company being the surviving corporation of the First Merger, also known as the “Surviving Entity”; and immediately
following the First Merger and as part of